Zoledronic acid induces apoptosis via stimulating the expressions of ERN1, TLR2, and IRF5 genes in glioma cells by Biray Avci, C. et al.
ORIGINAL ARTICLE
Zoledronic acid induces apoptosis via stimulating the expressions
of ERN1, TLR2, and IRF5 genes in glioma cells
Cigir Biray Avci1 & Cansu Caliskan Kurt1 & Burcu Erbaykent Tepedelen2 &
Ozgun Ozalp1 & Bakiye Goker1 & Zeynep Mutlu1 & Yavuz Dodurga3 & Levent Elmas3 &
Cumhur Gunduz1
Received: 28 September 2015 /Accepted: 25 November 2015 /Published online: 8 December 2015
# International Society of Oncology and BioMarkers (ISOBM) 2015
Abstract Glioblastoma multiforme (GBM) is the most com-
mon and aggressive brain tumor that affects older people.
Although the current therapeutic approaches for GBM include
surgical resection, radiotherapy, and chemotherapeutic agent
temozolomide, the median survival of patients is 14.6 months
because of its aggressiveness. Zoledronic acid (ZA) is a
nitrogen-containing bisphosphonate that exhibited anticancer
activity in different cancers. The purpose of this study was to
assess the potential effect of ZA in distinct signal transduction
pathways in U87-MG cells. In this study, experiments per-
formed on U87-MG cell line (Human glioblastoma-astrocyto-
ma, epithelial-like cell line) which is an in vitro model of
human glioblastoma cells to examine the cytotoxic and apo-
ptotic effects of ZA. IC50 dose of ZA, 25 μM, applied on U87-
MG cells during 72 h. ApoDIRECT In Situ DNA
Fragmentation Assay was used to investigate apoptosis of
U87MG cells. The quantitative reverse transcription polymer-
ase chain reaction (qRT-PCR) (LightCycler480 System) was
carried out for 48 gene expression like NF-κB, Toll-like re-
ceptors, cytokines, and inteferons. Our results indicated that
ZA (IC50 dose) increased apoptosis 1.27-fold in U87MG cells
according to control cells. According to qRT-PCR data, ex-
pression levels of the endoplasmic reticulum-nuclei-1
(ERN1), Toll-like receptor 2 (TLR2), and human IFN
regulatory factor 5 (IRF5) tumor suppressor genes elevated
2.05-, 2.08-, and 2.3-fold by ZA, respectively, in U87MG
cells. Our recent results indicated that ZA have a key role in
GBM progression and might be considered as a potential
agent in glioma treatment.
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Introduction
Glioblastoma multiforme (GBM) is the most common and
aggressive brain tumor that affects older people. [1].
According to the World Health Organization (WHO) in
2007, GBM was determined as grade IV astrocytoma [2, 3].
Although the current therapy approaches for GBM are surgi-
cal resection, radiotherapy, and chemotherapeutic agent tem-
ozolomide, the median survival of patients is 14.6 months
because of its aggressiveness [4, 5]. There is a need to inves-
tigate new therapeutic approaches for GBM due to the short-
ened survival of patients.
Synthe t ic ana logues of pyrophosphate cal led
bisphosphonates (BPs) act as efficient inhibitors of osteoclas-
tic bone resorption [6, 7]. BPs consist of three generations that
differ from their structure in R1 side chain. Both first and
second generations do not include any nitrogen in the R1
chain, but third group of BPs has nitrogen in circular structure
[7]. Zoledronic acid (ZA), a third-generation bisphosphonate,
exhibited anticancer activity in various metastatic cancers in-
cluding breast, prostate, lung cancer, and multiple myeloma
with skeletal complications of bone metastasis [8, 9]. The
possible mechanism of ZA in blocking osteoclast-mediate
bone absorption is the inhibition of the farnesyl diphosphate
synthase which is the key enzyme of the mevalonate pathway.
Through this mechanism, farnesyl diphosphate and its
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downstream geranylgeranyl diphosphate are inhibited, and
thus, small GTPases including Ras, Rho, and Rab which reg-
ulate osteoclast cannot be post-translated [10].
In recent years, direct or indirect effects of ZA on cancer
cells have been shown in several studies. These studies show
that ZA has anti-proliferative, proapoptotic, and anti-invasive
activities and anti-angiogenic and immunomodulatory abili-
ties [11]. Moreover, ZA has been used as a new therapeutic
approach in combination with various agents such as cisplatin,
etoposide, doxorubicin, paclitaxel, irinotecan, and imatinib,
because of the synergistic effects of these combinations in
various cancer cells [11].
The purpose of this study was to assess the potential effect
of ZA on the expression of 48 genes in distinct signal trans-
duction pathways in U87-MG cells.
Materials and methods
Chemicals
Zoledronic acid was obtained from Sigma-Aldrich (St. Louis,
Missouri, USA). ZAwas diluted in distilled water and stored as
10-mM stock solution at −20 °C. Prior to experiments, different
concentrations of ZAwere prepared from stock solution.
Cell culture
U87-MG cell line was obtained from American Type Culture
Collection (ATCC, Manassas, VA). U87-MG cells were seed-
ed into 75-cm2 tissue culture flask. They were maintained in
BIO-AMF-1 basal medium containing 2 mM L-glutamine
supplemented with 50 ml BIO-AMF-1 supplement and 1 %
penicillin/streptomycin in a standard cell culture incubator at
37 °C, 95 % relative humidity, and 5 % CO2 atmosphere.
Determination of cytotoxicity
Cytotoxicity of ZA in U87-MG cells was assessed by WST-1
[2-(4-iodofenil)-3-(4-nitrofenil)-5-(2,4-disülfofenil)-2H-tetra-
zolium sodium salt] assay (Roche). Cells were seeded in 96-
well culture plate at a concentration of 5×103 cells/well and
incubated overnight for their adhesion to plate surface. Cells
were treated in the range of 10–100-μM doses of ZA for 72 h.
After treatment, 10-μL WST-1 reagent was added per well.
Formazan formation was quantified spectrophotometrically at
480 nm (reference wavelength 620 nM) by using a microplate
reader (Bio-Rad, Coda, Richmond, CA).
Apoptotic DNA fragmentation assay
To detect the apoptotic effect of ZA to DNA Fragmentation on
U87-MG cells, ApoDIRECT In Situ DNA Fragmentation
Assay (BD Pharmingen) was performed by flow cytometry.
For fixation procedure, 1–2×106 untreated cells and ZA-
treated cells were suspended in 1 % paraformaldehyde in
PBS. After centrifugation steps, according to kit protocol,
cells were treated with 70 % ice-cold ethanol for 30 min.
For staining protocol, cells were suspended in DNA
Labeling Solution prepared as described in the kit for
60 min at 37 °C. At the end of the incubation time, cells were
treated with rinse buffer followed by centrifugation. After re-
moving the supernatant, cell were resuspended in PI/RNase
staining buffer and incubated at room temperature for 30 min.
Then, PI/RNase-treated cells were analyzed by flow
cytometry.
RNA isolation and cDNA synthesis
Total RNAwas isolated from U87-MG cells treated with IC50
dose (72 h) of ZA and untreated control cells (High Pure RNA
Isolation Kit - Roche). Reverse transcription procedure was
performed for complementary DNA (cDNA) synthesis by
using Transcriptor High Fidelity cDNA Synthesis Kit
(Roche Diagnostics, Germany) according to the instructions
of manufacturers.
Quantitative real-time PCR
Custom RT2 PCR Array (Roche Diagnostics, Germany) was
used to evaluate the quantitative gene expression analysis of
48 genes including housekeeping genes with LightCycler 480
quantitative reverse transcription polymerase chain reaction
(qRT-PCR) system. The expression values of these genes were
proportioned to housekeeping genes (18S ribosomal RNA and
GAPDH) to calculate the relative expression ratios. List of the
genes is shown in Table 1.
Statistical analysis
Cytotoxicity analysis was calculated by GraphPad Prism v5.0
Software. Data analysis was evaluated byΔΔCTmethod and
quantitated by BLightCycler 480 Quantification Software,^
and statistical analysis was evaluated by web-based RT2
Profiler PCR Array Data Analysis version 3.5. The p value
calculation was based on a Student’s t test of the replicate
2−ΔCt values for each gene in the control group and treatment
groups. A value of P<0.05 was considered as significant.
Results
Cytotoxicity assay (WST-1 assay)
The cytotoxic effect of ZA on U87-MG cells was determined
by WST-1 cytotoxicity assay as described in BMaterials and
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methods.^ Concentration doses of ZA were prepared in the
range of 10–100 μM and treated 5×103 U87-MG cells per
well. Data of the cytotoxic effect of ZA was assessed at
24th, 48th, and 72nd hours. The viability of U87-MG cells
decreased in a time- and dose-dependent manner. In the pres-
ent study, IC50 doses of ZA in U87-MG cells were calculated
as 25 μM at 72nd hours via WST-1 assay (Fig. 1).
Determination of apoptotic DNA fragmentation assay
by flow cytometry
Apoptotic effects of ZA on U87-MG cells were analyzed by a
commercial kit according to the protocol of the manufacturer.
Initially, U87-MG cells were cultured at 1–2×106 cells. After
we had enough cell density, cells were fixed and stained, re-
spectively, according to the protocol. At the end of all steps,
apoptotic status of U87-MG cells treated with 25 μM of ZA
was analyzed by flow cytometry. Our flow cytometry data
indicated that apoptosis was increased 4.25-fold by ZAwhen
compared to control cells untreated with ZA (Fig. 2). Also, we
found that ZA induced apoptosis 1.14- and 2.33-fold at 24th
and 48th hours, respectively.
Real-time PCR
Afterwards total RNA isolation from control and ZA-treated
cells by using commercial kit, cDNA synthesis was performed
by Transcriptor First Strand cDNA Synthesis Kit (Roche
Diagnostics, Germany) as first step of reverse transcription.
Custom RT2-PCR array was performed to evaluate the quan-
titative gene expression analysis including housekeeping
genes at LightCycler 480 qRT-PCR platform. The results of
expression were proportioned to expression of 18S ribosomal
RNA and GAPDH (housekeeping genes) to calculate the rela-
tive expression ratios. We totally investigated the expression
of 48 genes which serve in distinct signal transduction path-
ways in U87-MG cells. Gene expression results regarding
IC50 dose of ZA showed that ERN1, TLR2, and IRF5 tumor
suppressor gene expressions were detected 2.05-, 2.08-, and
2.3-fold, respectively, according to untreated U87-MG control
cells (p<0.05).
Discussion
Some of the cancers have ability to metastasize to their spe-
cific tissues by using lymphatic and blood-flow patterns, their
cellular adhesion molecules and receptors and the cytokine
signals which they can synthesize or they can react [12]. A
dynamic and vascularized bone tissue provides a hematopoi-
etic environment for cancer stem cells [12]. Bone can dis-
charge some factors which cancer cells respond so that it can
play role in metastasis development. Therefore, patients with
metastatic cancers such as multiple myeloma (95–100 %),
breast (75 %) or prostate, lung (40 %) and renal cell cancers
metastasize to the bone [13]. As a result, researchers have
aimed to develop new drug strategies to treat bone metastasis
for many years.
Table 1 List of the genes
Position Gene symbol Position Gene symbol
A1 XBP1 E1 NFKB1
A2 ERN1 E2 NFKB2
A3 PAX5 E3 IKBKG
A4 AICDA E4 IKBKB
A5 BCL6 E5 NFKBIA
A6 PRDM1 E6 REL
B1 MTA3 F1 RELA
B2 CYP27B1 F2 RELB
B3 TNFRSF11A F3 IRF3
B4 TNFSF11 F4 IRF7
B5 TNFRSF11B F5 IRF5
B6 TLR1 F6 ACTB
C1 TLR2 G1 IFNA1
C2 TLR3 G2 IFNG
C3 TLR4 G3 TNF
C4 TLR5 G4 MAP3K7
C5 TLR6 G5 MAP2K3
C6 TLR7 G6 GAPDH
D1 TLR8 H1 MAP2K6
D2 TLR9 H2 MAPK14
D3 FKBP1A H3 MAP2K4
D4 MTOR H4 MAPK8
D5 RPS6KB1 H5 MAP3K2
D6 AKT1 H6 18S RIBOSOMAL RNA
Fig. 1 Effect of zoledronic acid on the cell viability of U87-MG cells.
The cells were treated with 0–100-μM zoledronic acid during 72 h. Cell
viability was calculated by WST-1 cell viability assay. Data are the aver-
age results of three independent experiments (IC50 dose of ZA in U87-
MG cells was determined as 25 μM at 72th hour
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Bisphosphonates (BPs) are the non-hydrolytic synthet-
ic analogues of inorganic pyrophosphate by substitution
of the oxygen atom with a carbon molecule that were
used as a potential inhibitor of bone resorption over
40 years [14, 15]. BPs are primarily bound to the bone
and absorbed by osteoclasts, so this absorption causes
inhibition of bone resorption and osteoclast apoptosis
[16]. BPs show whether their effectiveness includes ni-
trogen [17]. Non-nitrogen-containing group called as
early-generation BPs that are ingested by osteoclasts into
non-hydrolysable analogues of adenosine triphosphate
leading to inhibition of cellular function ultimately re-
sults in cell death [15]. Nitrogen-containing BPs (N-
BPs) show their effect by inhibiting mevalonate pathway
via diminishing activity of farnesyl pyrophosphate
synthase (FPP); thus, they reduce cellular protein
prenylation which is vital for function and survival [15,
17, 18]. Berenson J. reviewed that BPs play an important
role in induction of apoptosis, prevention of tumor cell
proliferation, blocking of angiogenesis, inhibition of cell
migration, prevention of tumor cell invasion, decrease in
adhesion of tumor cells, reduction in tumor-infiltrating
and angiogenic macrophages, and stimulation of gamma
delta T cells [19]. In vitro studies revealed that BPs can
induce apoptosis on a large scale of human cancers in-
cluding melanoma, sarcoma, myeloma, leukemia, breast,
colon, lung, prostate, and pancreas [18, 20–24]. Also,
these studies showed that N-BPs induce apoptosis with
low concentrations compared to early-generation BPs.
ZA, a heterocyclic and nitrogen-containing bisphospho-
nate, is an effective inhibitor of osteoclastic bone resorption,
and it functions to decrease bone resorption in patients with
osteoporosis in clinical practice [8, 25]. It is also used for the
treatment of tumor-induced hypercalcemia and the decline of
skeletal complications in solid tumors and multiple myeloma
[25]. Initially, despite its usage as an inhibitor of osteoclastic
bone resorption, current studies are focused on its direct anti-
cancer effect independently of osteoclastic bone resorption
effect. Direct anti-cancer effects of ZA were shown in some
cancer types such as breast, pancreatic, prostate, and multiple
myeloma [26, 27]. Nevertheless, its anti-cancer activity differ-
entiates due to type and origin of cancer. On the other hand,
the inhibitory effect of ZA and its molecular mechanism are
not so clear in glioblastomamultiforme. In the present study, it
FC:1.14 FC:2.33 FC:4.25
Fig. 2 Apoptotic effect of zoledronic acid depends on time and dosage.
U87-MG cells were treated 25μMZAduring 24, 48, and 72 h. Apoptotic
effects of ZAwere detected by commercial kit. Apoptotic status of U87-
MG cell treated with 25 μM ZAwas analyzed by flow cytometry (IC50
dose of ZA induced apoptosis 4.25-fold when compared to control cells
that untreated with ZA at 72th hours)
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has been aimed to investigate the possible effects of the third-
generation BPs, ZA on U87-MG glioblastoma cell line.
In this study, we first analyzed the effects of ZA on U87-
MG glioblastoma cell line. We treated the cells in the range of
10–100 μMZA for 24, 48, and 72 h. According to our WST-1
results, IC50 dose of ZA on U87-MG cells is 25 μM at 72nd
hour in dose-dependent manner. Reports on lung, breast, pros-
tate, osteosarcoma, and pancreatic cancers showed that 50 %
inhibitory concentration (IC50) of ZA was ranged from 1 to
100 μM depending on the cell viability assay [28–35].
Romani et al. reported that ZA inhibited cell growth in dose-
dependent manner in EGI-1 and TFK-1 cholangiocarcinoma
cell lines by using MTT assay with the IC50 range from 17 to
37 mM for cells, respectively [36]. Koto and colleagues
showed that ZA inhibited the growth of HT1080 fibrosarcoma
cells in a time- and dose-dependent manner and by using
trypan blue dye exclusion method. The IC50 of ZA after 48
and 72 h of treatment was calculated as 1.66 and 1.26 μM,
respectively [37]. In a previous study, in vitro treatment of
HCT-116 colon carcinoma cells with the range of 0–50 μM
ZA reduced cell growth dependently, after 5 days treatment
with 50 μM ZA resulting in more than 90 % decrease in the
number of viable cells as compared to untreated control
groups [22]. By using MTS cell viability assay, Liu et al.
reported that the range of 0–200 μM ZA inhibited NB4 acute
promyelocytic leukemia cells in a dose-dependent manner at
48 and 72 h. The highest inhibition rate was observed at
200 μM on NB4 cells [38]. Karabulut et al. used XTT cell
viability assay in order to analyze the effect of ZA in ovarian
cancer, and they showed that IC50 values of ZA were calcu-
lated as 15.5 and 13 μM on OVCAR-3 and MDAH-2774
cells, respectively [39]. Porru et al. studied on pcDNA3-luc-
transfected U373 (U373MG-LUC) cells, and the analysis of
U373MG-LUC cell growth in terms of MTT assay demon-
strated that IC50 dose of ZAwas 46 μM [40].
Several previous in vitro studies showed that ZA can in-
duce apoptosis of tumor cell in a wide range of human and
murine cancer cell lines [41–43]. The former studies demon-
strated that ZA-induced apoptosis occurred by activation of
caspase-3/7 signaling pathway. A previous study on HCT-116
colon carcinoma cells suggested that ZA induced apoptosis
through the activation of the mitochondrial pathway, includ-
ing caspase-8-mediated Bid activation, Bax translocation, cy-
tochrome c release, and eventually activation of the caspase-3
and caspase-7. This study also showed that ZA activated mi-
tochondrial pathway simultaneously releases AIF into the cy-
tosol [22]. Tamura et al. reported that treatment of ZA on
HSC-3 oral carcinoma cells induced apoptosis via caspase-3,
caspase-8, caspase-9 activation, PARP and Bid cleavage, and
decreased Bcl-2 levels [7]. Liu and their colleagues performed
ZA treatment on NB4 acute promyelocytic leukemia cells,
and they observed that the rate of apoptosis was significantly
higher in the ZA-treated cells. They also reported that ZA
upregulated the expression of cleaved caspase-3 and cleaved
PARP, downregulated the Bcl-2 and Bcl-xL expressions at
lower levels, expressed the Bax and Puma, and cleaved
caspase-9 at higher levels [38]. Wang and colleagues demon-
strated that treatment of ZA on cervical cancer cells caused a
dose- and time-dependent PARP cleavage and the activation
of caspase-3 signaling pathway. In order to confirmmitochon-
drial apoptosis, they examined the Bcl-2/Bax ratio mRNA
expression in three cervical cancer cell lines. ZA increased
Bcl-2/Bax ratio, and they suggested that ZA leads to mito-
chondrial membrane disruption and so initiates the mitochon-
drial apoptosis [44]. Rachner et al. quantified the percentage
of apoptosis with ZA treatment onMDA-MB-231 andMCF-7
breast cancer cells by using annexin V/PI technique. They
showed that percentage of apoptosis increased from 3.1 to
26.3 % (by 8.5-fold) in MDA-MB-231 cells after 72 h of
ZA exposure, whereas the annexin V-fraction of MCF-7 cells
only increased from 4.2 to 7.8 %. They also indicated that ZA
induced the cleavage of caspase-3, caspase-7, and PARP only
in MDA-MB-231 cells [31]. On the other hand, treatment of
ZA in pancreatic cancer cell leads to activation of caspase-9
pathway, but not caspase-3 cascade [35]. Salvatore et al.
showed that ZA increased apoptosis (43 %) significantly on
non-small cell lung cancer cells compared to untreated cells
[28]. Mani et al. investigated the effect of ZA on PC-3, DU-
145, and LNCaP prostate cancer cells, and they observed that
the Annexin V/PI assay demonstrated early apoptosis in PC-3
and DU-145 and late apoptosis in LNCaP cells only at
100 mM ZA [32]. In line with the literature, we examined that
IC50 dose of ZA induced apoptosis 4.25-fold in U87-MG
glioblastoma cells when compared to control cells. Also, we
saw that ZA induced apoptosis 1.14- and 2.33-fold at 24th and
48th hours, respectively. In the light of these data, it may be
suggested that ZA exhibits different apoptotic pathways de-
pending on cell types.
According to our knowledge from literature, in vitro stud-
ies for inhibitory effects of ZA and its mechanism on glioblas-
toma are limited and unsatisfying. Cimini et al. evaluated
whether ZA treatment would make glioma cell lines more
susceptible to lysis by in vitro expanded Vδ2 T-cells, improv-
ing their antitumor activity. They reported that ZA enhanced
Vδ2 T-cell antitumor response to human glioma cell lines and
ZA synergistically elevated the Vδ2 T-cell-mediated apoptosis
of glioblastoma cell lines [44]. Nakazawa and colleagues
demonstrated that ZA significantly enhanced the γδT cell-
mediated killing of U87MG, U138MG, and A172 GBM cell
lines, and they suggested that combination of the γδT cell-
targeting therapy with ZA might be effective for GBM pa-
tients [45]. Fukai et al. investigated whether ZA can be an
effective adjuvant to temozolomide (TMZ) in human malig-
nant glioma cells which express MGMT. Combination of
TMZ and ZA resulted in a significant decrease in cell growth,
an increased apoptotic rate and significant activation of
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caspase-3 and PARP. Beside this, they obtained decreased
amounts of Ras-GTP, MAPK, and Akt phosphorylation and
MGMT expression only in ZA-treated cells. They also
showed that combined TMZ and ZA treatment lead to signif-
icant decrease in tumor growth in subcutaneous xenograft
models [46]. In this study, we evaluated the expression of
several genes including several signal transduction pathways
such as cytokines and costimulator molecules, interferons,
NF-κB and Toll-like receptors in U87-MG cells by using
real-time PCR method. Our study showed that IC50 dose of
25 μM ZA significantly resulted in increased ERN1, TLR2,
and IRF5 genes expressions with fold changes of 2.05-, 2.08-,
and 2.3-fold, respectively, compared with untreated U87-MG
control cells. Our data suggest that ZA may induce apoptosis
through enhancing the expressions of ERN1, TLR2, and IRF
genes in glioma cells. To our knowledge, this is the first report
of ZA that induced the expression of these genes in
glioblastoma.
In conclusion, a distinct increase in apoptosis was observed
following the treatment of glioblastoma cells with 25 μM of
zoledronic acid. These novel findings showed that ZA might
be important in prognosis of glioma, and it is aimed to ques-
tion if it could be used as a target substance in glioma treat-
ment with further research. Based on the mentioned informa-
tion and results, due to its feature for crossing the blood–brain-
barrier (BBB), ZAmay be an effective and alternative therapy
to treat glioblastoma. Further studies are needed to clarify its
mechanism of ZA in different types of glioma cell lines.
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